Dechert LLP

BioDech

Arts EN ↓ Epizody: 6

In today's competitive landscape, life sciences companies routinely face a myriad of legal complexities and regulatory issues, from early-stage financing for clinical trials and IPO preparedness, to antitrust, securities or patent disputes post-product launch. Despite the challenges, innovation in the market is more active than ever. To help companies navigate these issues, BioDech brings together life sciences industry leaders with lawyers from Dechert’s cross-practice global life sciences team to discuss the challenges and opportunities that may arise at every phase of the life sciences life...

Určitě navštivte web podcastu a podpořte jeho tvůrce: www.buzzsprout.com

Autor

Dechert LLP

Kategorie

Arts

Web podcastu

www.buzzsprout.com

Nejnovější epizoda

14. zář 2023

Kde poslouchat?

Podcasty v aplikaci Replaio Radio Už brzy

Podcasty míří do aplikace už brzy. Nainstaluj si ji teď a jako první uvidíš úplně nový pohled na podcasty

Nainstaluj zdarma Android téměř 10 mil. stažení · hodnocení 4,7+ iOS už brzy

Epizody

One in Four: What Makes Life Sciences Companies So Vulnerable to Securities Class Actions 14.09.2023 30:28

Securities class actions are on the rise and life sciences organizations are of specific interest to regulators. In our sixth episode of BioDech, a global life sciences broadcast series, Joni Jacobsen , co-chair of the global securities and complex litigation team and Angela Liu , securities litigation partner are joined by Tiffany Engsell , Senior Counsel, Litigation & Government Investigati...

Episode 5 | Executive Compensation Considerations for a Successful IPO 15.05.2023 31:42

Executive compensation plays a critical role in preparing for a successful IPO. In the fifth episode of BioDech, a global life sciences broadcast series, Kevin Kay , partner in Dechert's Employee Benefits and Executive Compensation practice, is joined by guest speakers John Schultz, Managing Director and co-head of the Compensation and Benefits practice at Alvarez & Marsal, and Brennan Ri...

Episode 4 | What Every Life Sciences Company Needs to Know About Cybersecurity 18.04.2023 35:53

Cybersecurity is the number one topic that keeps boards and executives up at night. Threats of all kinds – from nation states to organized crime – are eager to steal the most valuable information and hold your company ransom, among other cyber threats. In our fourth episode of BioDech, Brenda Sharton , partner and Chair of Dechert’s top ranked, global Privacy & Cybersecurity practice, and Sop...

Episode 3 | Corporate Governance Considerations Pre-IPO 21.03.2023 44:02

In the third episode of BioDech, a global life sciences broadcast series, Jolie Siegel, Chief Legal Officer of C4 Therapeutics, Inc. , and Marco Taglietti, M.D., Independent Board Director of Aquestive Therapeutics , join Dechert's John Alessi and Stephen Leitzell to discuss corporate governance considerations leading up to an IPO, including board composition, financial controls and overall...

Episode 2 | Choosing an Investment Bank 21.02.2023 29:35

In our second episode of BioDech, a global life sciences broadcast series, David Rosenthal , corporate and securities partner and co-lead of the firm's life sciences practice, is joined by guest speakers Gregg Beloff , co-founder and managing director of Danforth Advisors, Gabe Cavazos, senior managing director in investment banking at SVB Securities, and Mark Hahn , CFO of Verona Pharma, to...

Episode 1 | When Do You Know You’re Ready to Go Public? 18.01.2023 23:28

As a biotech company, how do you determine when you are ready to go public? Our inaugural episode of BioDech, a global life sciences broadcast series, features guest speaker Philip Ross , global chairman of J.P. Morgan Investment Banking, and Dechert's Anna Tomczyk and Gregory Schernecke , partners in the firm's corporate and life sciences practices. Learn more.